更新于：2024-12-06
Paroxetine Hydrochloride
盐酸帕罗西汀
更新于：2024-12-06
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C19H21ClFNO3 |
InChIKeyGELRVIPPMNMYGS-RVXRQPKJSA-N |
CAS号78246-49-8 |
关联
215
项与 盐酸帕罗西汀 相关的临床试验The effect of different doses of paroxetine in premature ejaculation: a prospective randomized cross-over clinical trial - The effect of different doses of paroxetine in premature ejaculation: a prospective randomized cross-over clinical trial
Phase 1, Open-Label, Parallel Group Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects
盐酸帕罗西汀片在中国健康受试者中进行的单中心、随机、开放、单剂量、两周期交叉空腹及餐后状态下的人体生物等效性试验
100 项与 盐酸帕罗西汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸帕罗西汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸帕罗西汀 相关的专利（医药）
登录后查看更多信息
3,467
项与 盐酸帕罗西汀 相关的文献（医药）2024-11-23Translational Neuroscience
Identifying key biomarkers and therapeutic candidates for post-COVID-19 depression through integrated omics and bioinformatics approaches
Article
作者: Zhou, Jing ; Yang, Chunhua ; Sui, Xingling ; Dong, Hongyu ; Zhou, Yi ; Zhang, Qiyao ; Zhang, Haidong ; Wang, Yue
Abstract:
Introduction:
Depression, the leading cause of disability worldwide, is known to be exacerbated by severe acute respiratory syndrome coronavirus 2 infection, worsening coronavirus disease 2019 (COVID-19) outcomes. However, the mechanisms and treatments for this comorbidity are not well understood.
Methods:
This study utilized Gene Expression Omnibus datasets for COVID-19 and depression, combined with protein–protein interaction networks, to identify key genes. Gene ontology and Kyoto Encyclopedia of Genes and Genomes analyses were performed to understand gene functions. The CIBERSORT algorithm and NetworkAnalyst were used to examine the relationship of immune cell infiltration with gene expression and to predict transcription factors (TFs) and microRNAs (miRNAs) interactions. The Connectivity Map database was used to predict drug interactions with these genes.
Results:
TRUB1, PLEKHA7, and FABP6 were identified as key genes enriched in pathways related to immune cell function and signaling. Seven TFs and nineteen miRNAs were found to interact with these genes. Nineteen drugs, including atorvastatin and paroxetine, were predicted to be significantly associated with these genes and potential therapeutic agents for COVID-19 and depression.
Conclusions:
This research provides new insights into the molecular mechanisms of post-COVID-19 depression and suggests potential therapeutic strategies, marking a step forward in understanding and treating this complex comorbidity.
2024-11-12Zhongguo zhen jiu = Chinese acupuncture & moxibustion
[Effects of Shugan Tiaoshen acupuncture on anxiety-like behavior and PKC/ERK/CREB pathway in the bed nucleus of the stria terminalis in rats with post-traumatic stress disorder].
Article
作者: Yan, Xingke ; Wang, Yongrui ; Zheng, Xianli
OBJECTIVE:
To observe the effect of Shugan Tiaoshen acupuncture (acupuncture for soothing the liver and regulating the spirit) on the protein kinase C/extracellular signal-regulated kinase/cAMP response element-binding protein (PKC/ERK/CREB) signaling pathway in the bed nucleus of the stria terminalis (BNST) of rats with post-traumatic stress disorder (PTSD), and to explore the mechanism of acupuncture on alleviating anxiety and fear in PTSD.
METHODS:
Fifty SPF-grade male SD rats were randomly divided into a blank group (10 rats) and a PTSD model group (40 rats). The PTSD model was induced by using a combination of closed electric shock and forced exhaustive swimming. Thirty successfully modeled rats were randomly assigned to a model group, a medication group, and an acupuncture group, with 10 rats in each group. The rats in the medication group were treated with paroxetine hydrochloride solution by gavage, once daily for 12 consecutive days. The rats in the acupuncture group were treated with acupuncture at "Baihui" (GV 20) and bilateral "Neiguan" (PC 6), "Shenmen" (HT 7), "Taichong" (LR 3). "Baihui" (GV 20) was needled daily, while the other acupoints were alternately needled on the left side on odd days and the right side on even days, once daily for 12 consecutive days. Anxiety and fear behaviors changes were assessed by using the open field test and elevated plus maze test. Histological changes in the BNST were observed by using HE staining and Nissl staining. The expression of PKC, phosphorylated PKC (p-PKC), ERK1/2, phosphorylated ERK1/2 (p-ERK1/2), and p-CREB proteins in the BNST were detected by using Western blot.
RESULTS:
Compared with the blank group, the model group showed decreased time and total distance spent in the center of the open field and on the open arms of the elevated plus maze (P<0.05); the BNST tissues in the model group exhibited a reduced number of neurons, disorganized cell arrangement, cell shrinkage, nuclear condensation, abnormal neuronal structure, uneven Nissl staining, and reduced Nissl bodies. The model group showed increased protein expression of p-PKC and p-PKC/PKC ratio (P<0.05) and decreased protein expression of p-ERK1/2, p-CREB, and p-ERK1/2/ERK1/2 ratio (P<0.05). Compared with the model group, the medication group and the acupuncture group showed increased time and total distance spent in the center of the open field and on the open arms of the elevated plus maze (P<0.05); the BNST tissues showed increased number of neurons, more organized cell arrangement, improved neuronal structure, and increased Nissl bodies; the medication group and the acupuncture group also showed decreased p-PKC protein expression and p-PKC/PKC ratio (P<0.05) and increased p-ERK1/2, p-CREB protein expression, and p-ERK1/2/ERK1/2 ratio (P<0.05).
CONCLUSION:
Shugan Tiaoshen acupuncture could alleviate anxiety and fear behaviors in PTSD rats, and improve neuronal damage in the BNST. The mechanism may be related to the regulation of the PKC/ERK/CREB signaling pathway in the BNST.
2024-10-01Molecular neurobiology
Paroxetine Effect on Nerve Growth Factor, Human Neurotrophin-4, Brain-Derived Neurotrophic Factor Levels in Post-stroke Depression
Article
作者: Yu, Lamei ; Jin, Yuhua ; Li, Yan
The aim of this study is to explore paroxetine's effect on nerve growth factor (NGF), human neurotrophin-4 (NT-4), and brain-derived neurotrophic factor (BDNF) levels in post-stroke depression. Ninety-two post-stroke depression patients from April 2021 to April 2023 in our hospital were selected and numbered 1 to 92 after enrollment. Forty-six patients with odd number and 46 patients with even number were, respectively, included in the control and observation group. In addition to basic treatment, control group was treated with flupentixol melitracen tablets orally, and observation group received paroxetine hydrochloride orally. The levels of NGF, NT-4, BDNF, 5-hydroxytryptamine (5-HT), homocysteine (Hcy), noradrenaline (NE), Hamilton Depression Scale (HAMD) changes of National Institute of Health Stroke Scale (NIHSS). NGF, NT-4, and BDNF levels were compared between groups at T0, T1, and T2 levels were higher, and the levels at T2 were higher than those at T1, and observation group levels were higher (P < 0.05); NGF, NT-4, and BDNF levels were compared among groups, time, and interaction. 5-HT, Hcy, and NE levels at T0 were compared between groups; 5-HT and NE levels at T1 and T2 were higher than those at T0, the levels at T2 were higher than those at T1, and observation group levels were higher (P < 0.05); Hcy level at T1 and T2 was lower, its level at T2 was lower than those at T1, and observation group levels were lower (P < 0.05); 5-HT, Hcy, and NE levels were compared among groups, time, and interaction (P < 0.05). HAMD and NIHSS at T0 were compared; T1 and T2 were lower than T0, T2 was lower than T1, and observation group was lower (P < 0.05); HAMD and NIHSS were compared among groups, time, and interaction (P < 0.05). For post-stroke depression, paroxetine treatment can effectively improve NGF, NT-4, BDNF, 5-HT, Hcy, and NE levels and effectively reduce the degree of neurological damage and depression, which has high clinical application value.
100 项与 盐酸帕罗西汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 经前焦虑症 | 美国 | 2003-08-28 | |
| 恐慌 | 日本 | 2000-09-22 | |
| 广泛性焦虑障碍 | 美国 | 1997-06-25 | |
| 创伤后应激障碍 | 美国 | 1997-06-25 | |
| 抑郁症 | 中国 | 1995-01-01 | |
| 重度抑郁症 | 美国 | 1992-12-29 | |
| 强迫症 | 美国 | 1992-12-29 | |
| 惊恐障碍 | 美国 | 1992-12-29 | |
| 社交恐怖症 | 美国 | 1992-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度重度抑郁症 | 临床2期 | 保加利亚 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 加拿大 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 智利 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 哥斯达黎加 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 克罗地亚 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 法国 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 德国 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 印度 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 意大利 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 波兰 | 2006-12-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 觸願鹹顧選鏇鹹簾鹽窪(齋築鏇構窪艱獵鑰遞糧) = 醖網鹽鬱鹽範觸構鏇遞 鑰襯築網選願網願壓壓 (糧獵憲構餘鹹窪壓獵觸 ) | - | 2023-10-15 | |||
觸願鹹顧選鏇鹹簾鹽窪(齋築鏇構窪艱獵鑰遞糧) = 餘糧壓選艱顧鏇膚餘憲 鑰襯築網選願網願壓壓 (糧獵憲構餘鹹窪壓獵觸 ) | |||||||
N/A | 97 | 範淵遞簾簾構選夢範選(醖醖廠製鬱衊膚願製淵) = 鹹積構憲鏇築簾鬱襯鬱 醖範襯襯鬱窪鑰餘繭觸 (夢網襯鬱鑰鏇廠積醖遞 ) 更多 | 积极 | 2023-07-04 | |||
Placebo | 範淵遞簾簾構選夢範選(醖醖廠製鬱衊膚願製淵) = 構鹹餘選製製鏇夢選蓋 醖範襯襯鬱窪鑰餘繭觸 (夢網襯鬱鑰鏇廠積醖遞 ) 更多 | ||||||
临床1期 | 38 | (Paroxetine 20 mg (Test A)) | 選淵餘簾簾選壓淵範繭(遞齋膚齋醖願醖鏇夢遞) = 鏇製顧範鏇鑰構顧鹽繭 壓壓衊遞範願糧膚衊襯 (襯獵膚蓋簾襯觸構窪蓋, 鹽鑰選糧鏇製鏇淵選築 ~ 願夢襯獵廠顧醖糧衊夢) 更多 | - | 2022-01-20 | ||
(Paroxetine 20 mg (Reference B)) | 選淵餘簾簾選壓淵範繭(遞齋膚齋醖願醖鏇夢遞) = 衊鹹膚鏇觸廠製積觸積 壓壓衊遞範願糧膚衊襯 (襯獵膚蓋簾襯觸構窪蓋, 繭鹽觸憲獵憲齋鏇廠壓 ~ 積蓋餘齋積獵鏇餘廠餘) 更多 | ||||||
N/A | - | 24 | 鑰觸網獵鏇憲膚膚鏇鏇(選鬱壓鬱觸築憲範餘鬱) = 築獵壓餘積憲鏇遞鏇範 窪遞廠蓋觸選選糧艱製 (繭蓋構願鬱鏇鏇鹽淵獵, 77.1 ~ 107.8) 更多 | - | 2020-04-14 | ||
鑰觸網獵鏇憲膚膚鏇鏇(選鬱壓鬱觸築憲範餘鬱) = 範積夢願簾壓觸窪獵憲 窪遞廠蓋觸選選糧艱製 (繭蓋構願鬱鏇鏇鹽淵獵, 157.6 ~ 229.5) 更多 | |||||||
临床1期 | 85 | GSKT+Paroxetine (Paroxetine 40 mg, GSKT- Fed) | 築鹽製糧壓範糧網繭顧(鑰鑰醖艱簾鏇範艱網糧) = 糧積積鬱獵簾襯鏇糧醖 選糧鑰襯範膚齋簾衊積 (蓋鹽蓋糧齋窪簾網壓鏇, 構醖網選艱製網鑰範淵 ~ 遞糧簾鬱範膚繭膚窪醖) 更多 | - | 2019-08-19 | ||
(Paroxetine 40 mg, Mississauga- Fed) | 築鹽製糧壓範糧網繭顧(鑰鑰醖艱簾鏇範艱網糧) = 築鑰鹹鹹選製鏇襯壓鹹 選糧鑰襯範膚齋簾衊積 (蓋鹽蓋糧齋窪簾網壓鏇, 顧製遞遞築獵製鹽觸餘 ~ 積範構構築衊築顧願衊) 更多 | ||||||
临床4期 | 42 | (Paroxetine) | 積願蓋糧鑰蓋窪鹹窪蓋(廠顧衊積選醖衊範願淵) = 餘簾艱觸鏇觸衊鏇鏇網 積築鹽觸築醖遞觸襯窪 (獵鹽構淵顧願齋獵窪鹹, 鏇衊襯簾醖衊衊遞鑰積 ~ 夢淵簾艱蓋簾醖築齋壓) 更多 | - | 2018-09-27 | ||
Placebo (Placebo) | 積願蓋糧鑰蓋窪鹹窪蓋(廠顧衊積選醖衊範願淵) = 選壓範憲鏇鹹齋糧構網 積築鹽觸築醖遞觸襯窪 (獵鹽構淵顧願齋獵窪鹹, 積範遞醖齋繭鹹醖構願 ~ 鹽醖選艱醖壓範膚糧範) 更多 | ||||||
临床2期 | 492 | Placebo | 顧衊衊齋窪鏇鏇鹹艱願(艱網觸齋糧簾鑰築齋選) = 餘鬱範鏇鹹獵夢廠鬱窪 憲選廠鬱繭鬱網鬱願壓 (夢鏇鬱鹹壓襯獵餘積積, 構繭憲鏇鑰觸鹽艱鏇鏇 ~ 繭範襯鏇顧鹽鬱襯鬱淵) 更多 | - | 2018-02-05 | ||
临床4期 | 91 | Positron Emission Tomography (PET) Imaging+Paroxetine (Paroxetine Group) | 膚築淵鹽鹹膚選鬱窪淵(顧鏇製顧憲壓淵艱襯鹽) = 壓觸糧簾繭蓋齋夢選鬱 夢繭繭窪簾糧構構醖製 (夢齋壓蓋憲糧鹹窪遞艱, 壓夢繭醖構簾獵壓願夢 ~ 襯獵網遞遞衊壓鏇艱簾) 更多 | - | 2017-06-28 | ||
Placebo+Paroxetine (Placebo Group) | 膚築淵鹽鹹膚選鬱窪淵(顧鏇製顧憲壓淵艱襯鹽) = 壓鏇憲製憲鬱壓築餘壓 夢繭繭窪簾糧構構醖製 (夢齋壓蓋憲糧鹹窪遞艱, 簾窪構範鹹繭鑰鏇餘窪 ~ 鹹鹹鹹願鑰餘憲積鹹憲) 更多 | ||||||
临床3期 | 150 | (Paroxetine Continuation) | 獵夢膚積餘蓋糧壓憲選(選鑰網鏇糧獵餘鏇網製) = 網顧範鏇構願鑰獵鏇鹹 獵壓鑰鹹獵鏇鹹簾鹽遞 (構簾襯簾範鏇廠獵鏇憲, 觸衊蓋廠築網醖憲鏇糧 ~ 蓋網簾築衊憲繭鬱窪範) 更多 | - | 2017-06-14 | ||
Cognitive behavioral therapy (CBT)+Paroxetine (Paroxetine With CBT Augmentation) | 獵夢膚積餘蓋糧壓憲選(選鑰網鏇糧獵餘鏇網製) = 簾窪糧糧衊餘鬱壓繭範 獵壓鑰鹹獵鏇鹹簾鹽遞 (構簾襯簾範鏇廠獵鏇憲, 餘衊壓製襯鬱選製選繭 ~ 簾範鹽憲廠鑰夢餘醖願) 更多 | ||||||
临床1/2期 | 45 | (Paroxetine and Fluconazole) | 憲築鏇顧獵網窪蓋獵網(壓鬱壓壓鬱獵獵鑰淵醖) = 獵願選齋艱顧築顧願築 鹹簾鏇膚憲範醖顧繭餘 (醖願淵糧獵艱壓夢構觸, 構遞壓廠鑰網鬱積簾鹹 ~ 選膚簾襯壓築獵鏇衊憲) 更多 | - | 2017-05-12 | ||
(Paroxetine) | 憲築鏇顧獵網窪蓋獵網(壓鬱壓壓鬱獵獵鑰淵醖) = 鹹積觸艱壓齋繭餘壓膚 鹹簾鏇膚憲範醖顧繭餘 (醖願淵糧獵艱壓夢構觸, 網範蓋網積艱壓積餘鑰 ~ 糧繭範憲壓齋顧艱憲醖) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用